

Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/O4CE347A8F1EN.html

Date: September 2021 Pages: 79 Price: US\$ 125.00 (Single User License) ID: O4CE347A8F1EN

Abstracts

Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Oxford BioMedica Plc (Oxford Biomedica) is a biopharmaceutical company involved in the development and commercialization of gene-based medicines. It has LentiVector, a sector leading lentiviral vector delivery platform. Based on this platform the company has developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS) and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in Oxfordshire, the UK. Oxford BioMedica is headquartered in Oxford, the UK.

Oxford BioMedica Plc Key Recent Developments

Jul 15,2021: Oxford Biomedica appoints Dr. Michael Hayden as Non-Executive Director May 27,2021: Oxford BioMedica: Board change May 27,2021: Oxford Biomedica announce Board Change May 18,2021: Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine Apr 27,2021: Oxford Biomedica Announces Annual General Meeting

Key benefits of buying this profile include:



You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business



research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Oxford BioMedica Plc - Key Facts Oxford BioMedica Plc - Key Employees Oxford BioMedica Plc - Key Employee Biographies Oxford BioMedica Plc - Major Products and Services Oxford BioMedica Plc - History Oxford BioMedica Plc - Company Statement Oxford BioMedica Plc - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview Oxford BioMedica Plc - Business Description Other Break-up: Bioprocessing/Commercial Development Performance Other Break-up: Licence Fees, Milestones and Royalties Performance Other Break-up: Platform Overview Performance Other Break-up: Product Overview Performance **Geographical Segment: Europe** Performance Geographical Segment: Rest of World Performance **R&D** Overview Oxford BioMedica Plc - Corporate Strategy Oxford BioMedica Plc - SWOT Analysis SWOT Analysis - Overview **Oxford BioMedica Plc - Strengths** Oxford BioMedica Plc - Weaknesses Oxford BioMedica Plc - Opportunities



Oxford BioMedica Plc - Threats Oxford BioMedica Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Oxford BioMedica Plc, Recent Deals Summary

SECTION 5 - COMPANY'S RECENT DEVELOPMENTS

Jul 15, 2021: Oxford Biomedica appoints Dr. Michael Hayden as Non-Executive Director May 27, 2021: Oxford BioMedica: Board change May 27, 2021: Oxford Biomedica announce Board Change May 18, 2021: Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine Apr 27, 2021: Oxford Biomedica Announces Annual General Meeting Apr 15, 2021: Oxford Biomedica announces Preliminary results for the year ended 31 December 2020 Apr 06, 2021: Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for the manufacture and supply of viral vectors Feb 03, 2021: Oxford Biomedica: Board changes Jan 18, 2021: Prime Minister Boris Johnson formally opens Oxford Biomedica's manufacturing facility Oxbox Nov 23, 2020: Oxford Biomedica appoints Dr. Sam Rasty as Non-Executive Director

SECTION 6 – APPENDIX



Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Oxford BioMedica Plc, Key Facts Oxford BioMedica Plc, Key Employees Oxford BioMedica Plc, Key Employee Biographies Oxford BioMedica Plc, Major Products and Services Oxford BioMedica Plc, History Oxford BioMedica Plc, Other Locations Oxford BioMedica Plc, Subsidiaries Oxford BioMedica Plc, Key Competitors Oxford BioMedica Plc, Ratios based on current share price Oxford BioMedica Plc, Annual Ratios Oxford BioMedica Plc, Annual Ratios (Cont...1) Oxford BioMedica Plc, Annual Ratios (Cont...2) Oxford BioMedica Plc, Interim Ratios Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Oxford BioMedica Plc, Recent Deals Summary **Currency Codes Capital Market Ratios** Equity Ratios **Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios **Efficiency Ratios**



List Of Figures

LIST OF FIGURES

Oxford BioMedica Plc, Performance Chart (2016 - 2020) Oxford BioMedica Plc, Ratio Charts Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Oxford BioMedica Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Oxford BioMedica Plc (OXB) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/O4CE347A8F1EN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/O4CE347A8F1EN.html</u>